Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events (irAEs). Many of these are driven by the sam...

Descripción completa

Detalles Bibliográficos
Autores principales: Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., LeBoeuf, N. R., Lenihan, D., Onofrei, C., Shannon, V., Sharma, R., Silk, A. W., Skondra, D., Suarez-Almazor, M. E., Wang, Y., Wiley, K., Kaufman, H. L., Ernstoff, M. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697162/
https://www.ncbi.nlm.nih.gov/pubmed/29162153
http://dx.doi.org/10.1186/s40425-017-0300-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697162/
https://www.ncbi.nlm.nih.gov/pubmed/29162153
http://dx.doi.org/10.1186/s40425-017-0300-z

Ejemplares similares